Hakim Kharrat
Director of Genopole Enterprises
GenoPole
France
Biography
Hakim Kharrat holds both a PhD in molecular biology and an MBA in innovation and technologies management. He spent five years as a researcher at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, where he specialized in protein molecular biology and biophysics. Hakim Kharrat was the founder, chairman and CEO of MilleGen (a CRO with expertise in the discovery and genetic engineering of antibodies for cancer therapies), founder and CEO of Protenia (a CMO specialized in the engineering and production of recombinant proteins), and cofounder and CEO of SmartMabs (an immunotherapy company focused on the promising field of "immune checkpoints" and the development of novel anti-cancer antibodies). Dr. Kharrat became the Director of Genopole Enterprises in late October 2015.
Research Interest
Hakim Kharrat holds both a PhD in molecular biology and an MBA in innovation and technologies management. He spent five years as a researcher at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, where he specialized in protein molecular biology and biophysics. Hakim Kharrat was the founder, chairman and CEO of MilleGen (a CRO with expertise in the discovery and genetic engineering of antibodies for cancer therapies), founder and CEO of Protenia (a CMO specialized in the engineering and production of recombinant proteins), and cofounder and CEO of SmartMabs (an immunotherapy company focused on the promising field of "immune checkpoints" and the development of novel anti-cancer antibodies). Dr. Kharrat became the Director of Genopole Enterprises in late October 2015.
